Skip to main content
Premium Trial:

Request an Annual Quote

AVI BioPharma, Lorus Therapeutics, GeneGo and Invitrogen, and Mirus

Premium

AVI Presents Data Showing Antisense Compounds Inhibit Dengue Virus In Vitro

AVI BioPharma said this week that it has presented data from a preclinical study showing that the company’s antisense compounds are capable of inhibiting dengue virus.

“This presentation describes how AVI’s Neugene antisense compounds specifically block dengue viral replication in cell culture,” Patrick Iversen, senior vice president of research and development at AVI, said in a statement. “These results suggest that our Neugene antisense compound has therapeutic potential for the control of dengue virus infections.”

The study, said AVI, examined the ability of the company’s antisense compounds to inhibit the replication of dengue virus strains 1 through 4. The best antisense compounds were effective against viral infection in cultured cells and were found to inhibit viral titer by up to one million-fold, said the company.


Lorus Says Subsidiary Issued European Patent for Tumor Suppressor Gene

Lorus Therapeutics said this week that its antisense subsidiary, GeneSense Technologies, has received a European patent covering the treatment of cancer using a gene that suppresses the growth of malignant tumors.

The patent, entitled “Suppression of Malignancy Utilizing Ribonucleotide Ruductase R1,” covers the use of a vector delivery system to deliver the tumor suppressor gene sequence to cancer cells, said Lorus.

“The discovery of a gene that has the ability to suppress malignant growth is an important achievement for Lorus, and we are working vigorously to determine how this discovery can best be developed for the benefit of cancer patients,” Jim Wright, Lorus’ CEO, said in a statement. “Gene therapy is an exciting cutting-edge area of research and represents Lorus’ fourth core technology platform under development.”


GeneGo Inks Deal with Invitrogen

GeneGo, a Mich.-based company that develops computational platforms for data integration and analysis, said this week that it has signed a multi-year deal to develop “new capabilities” with Invitrogen.

Specific details of the arrangement were not disclosed, but will “be divulged in greater detail as milestones of the collaboration are achieved,” said GeneGo.


Mirus Reports Development of Gene Delivery Method

Mirus said this week that it has developed a method to deliver therapeutic genes to muscle via the blood stream.

The approach involved temporarily occluding blood flow in an arm or leg using a tourniquet or blood pressure cuff, then intravenously injecting a plasmid DNA solution, the company said. With the pressure elevated in the occlusion zone, the blood vessel wall becomes more permeable and the pDNA can migrate into the adjoining muscle cells. More details on the method will be reported in the journal Molecular Therapy, said Mirus.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.